TY - JOUR
T1 - Antiemetic effects of baclofen in a shrew model of postoperative nausea and vomiting
T2 - Whole-transcriptome analysis in the nucleus of the solitary tract
AU - Konno, Daisuke
AU - Sugino, Shigekazu
AU - Shibata, Tomoko F.
AU - Misawa, Kazuharu
AU - Imamura-Kawasawa, Yuka
AU - Suzuki, Jun
AU - Kido, Kanta
AU - Nagasaki, Masao
AU - Yamauchi, Masanori
N1 - Publisher Copyright:
© 2022 The Authors. CNS Neuroscience & Therapeutics published by John Wiley & Sons Ltd.
PY - 2022/6
Y1 - 2022/6
N2 - Aims: The molecular genetic mechanisms underlying postoperative nausea and vomiting (PONV) in the brain have not been fully elucidated. This study aimed to determine the changes in whole transcriptome in the nucleus of the solitary tract (NTS) in an animal model of PONV, to screen a drug candidate and to elucidate the molecular genetic mechanisms of PONV development. Methods: Twenty-one female musk shrews were assigned into three groups: the Surgery group (shrew PONV model, n = 9), the Sham group (n = 6), and the Naïve group (n = 6). In behavioral studies, the main outcome was the number of emetic episodes. In genetic experiments, changes in the transcriptome in the NTS were measured. In a separate study, 12 shrews were used to verify the candidate mechanism underlying PONV. Results: A median of six emetic episodes occurred in both the Sham and Surgery groups. Whole-transcriptome analysis indicated the inhibition of the GABAB receptor-mediated signaling pathway in the PONV model. Baclofen (GABAB receptor agonist) administration eliminated emetic behaviors in the shrew PONV model. Conclusions: Our findings suggest that the GABAB receptor-mediated signaling pathway is involved in emesis and that baclofen may be a novel therapeutic or prophylactic agent for PONV.
AB - Aims: The molecular genetic mechanisms underlying postoperative nausea and vomiting (PONV) in the brain have not been fully elucidated. This study aimed to determine the changes in whole transcriptome in the nucleus of the solitary tract (NTS) in an animal model of PONV, to screen a drug candidate and to elucidate the molecular genetic mechanisms of PONV development. Methods: Twenty-one female musk shrews were assigned into three groups: the Surgery group (shrew PONV model, n = 9), the Sham group (n = 6), and the Naïve group (n = 6). In behavioral studies, the main outcome was the number of emetic episodes. In genetic experiments, changes in the transcriptome in the NTS were measured. In a separate study, 12 shrews were used to verify the candidate mechanism underlying PONV. Results: A median of six emetic episodes occurred in both the Sham and Surgery groups. Whole-transcriptome analysis indicated the inhibition of the GABAB receptor-mediated signaling pathway in the PONV model. Baclofen (GABAB receptor agonist) administration eliminated emetic behaviors in the shrew PONV model. Conclusions: Our findings suggest that the GABAB receptor-mediated signaling pathway is involved in emesis and that baclofen may be a novel therapeutic or prophylactic agent for PONV.
UR - https://www.scopus.com/pages/publications/85125547539
UR - https://www.scopus.com/pages/publications/85125547539#tab=citedBy
U2 - 10.1111/cns.13823
DO - 10.1111/cns.13823
M3 - Article
C2 - 35238164
AN - SCOPUS:85125547539
SN - 1755-5930
VL - 28
SP - 922
EP - 931
JO - CNS Neuroscience and Therapeutics
JF - CNS Neuroscience and Therapeutics
IS - 6
ER -